Key Drivers
- Margin Compression
- Adequate Liquidity
- Dilution Risk
AIAI Summary
CLBT is now an execution-driven turnaround rather than a straightforward growth story: investors should wait for renewed ARR growth and margin recovery to validate that CMMC/IRAP eligibility converts into contracts, as another guidance reset, dilution, or legal overhang could drive further multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Adequate Liquidity
- •Dilution Risk
CLBT has strong annual profitability and liquidity, but recent margin deterioration, high valuation, and significant stock-based compensation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trading
- •Support holding
- •Resistance overhead
CLBT remains range-bound last month, with support at $11.20–$11.30 and a bullish trigger above $12.00–$12.29, while a break below $11.05 would increase downside risk.
No anomalous movement; price remained range-bound
Sentiment & News
Key News Insights:
- •Security Certifications
- •Legal Scrutiny
- •Analyst Support
Cellebrite's security advances and favorable analyst outlook support growth prospects, but recurring securities-law investigations and reduced institutional holdings elevate near-term risk.
The mixed news flow may sustain volatility, with legal developments likely outweighing operational positives in the near term
Similar Companies in Technology
Other companies in the same sector with AI ratings